China vs Iran, Islamic Republic of: Average cost of multi drug-resistant tuberculosis treatment
China
20,028 constant 2022 US$
in 2024
Iran, Islamic Republic of
28,730 constant 2022 US$
in 2022
China rank
4th
Iran, Islamic Republic of rank
3rd
Average cost of multi drug-resistant tuberculosis treatment over time
- China
- Iran, Islamic Republic of
How they compare
Iran, Islamic Republic of currently reports 28,730 constant 2022 US$ against 20,028 constant 2022 US$ in China, a difference of 8,702 constant 2022 US$.
That makes Iran, Islamic Republic of's figure about 1.4 times China's.
The two have swapped places 4 times across 6 shared years of data; in 2017 it was Iran, Islamic Republic of ahead.
China ranks 4th and Iran, Islamic Republic of ranks 3rd of 92 countries.
Across the 2 decades both report, China averaged higher in 1 and Iran, Islamic Republic of in 1.
Head to head by decade
| Decade | China | Iran, Islamic Republic of | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 6,001 constant 2022 US$ | 8,842 constant 2022 US$ | 2,841 constant 2022 US$ | Iran, Islamic Republic of |
| 2020s | 21,263 constant 2022 US$ | 20,687 constant 2022 US$ | 576.33 constant 2022 US$ | China |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of multi drug-resistant tuberculosis treatment, China or Iran, Islamic Republic of?
- Iran, Islamic Republic of, at 28,730 constant 2022 US$ against 20,028 constant 2022 US$ in China as of 2022.
- What is the difference in average cost of multi drug-resistant tuberculosis treatment between China and Iran, Islamic Republic of?
- 8,702 constant 2022 US$, with Iran, Islamic Republic of ahead.
- How many years of comparable data are there for China and Iran, Islamic Republic of?
- 6 years are reported by both, from 2017 to 2022.
- How do China and Iran, Islamic Republic of rank globally for average cost of multi drug-resistant tuberculosis treatment?
- China ranks 4th and Iran, Islamic Republic of ranks 3rd of 92 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of multi drug-resistant tuberculosis treatment. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting multidrug-resistant tuberculosis treatment, excluding buffer stock.